Ayahuasca e saúde mental: efeitos do seu uso associado a casos de depressão

Lucas Daniel dos Santos; Wallisten Passos Garcia

doi:10.5433/2236-6407.2023.v14.47818

Authors

Lucas Daniel dos Santos Pontifícia Universidade Católica do Paraná (PUCPR) https://orcid.org/0000-0003-1542-8360
Wallisten Passos Garcia Pontifícia Universidade Católica do Paraná (PUCPR) https://orcid.org/0000-0003-2518-7345

DOI:

https://doi.org/10.5433/2236-6407.2023.v14.47818

Keywords:

ayahuasca, neurochemical interaction, depression, mental health

Abstract

The increase in cases of depression in the world's population leads to questioning the effectiveness of pharmacological treatments and encourages the search for alternative treatments. Studies about ayahuasca and your effects on depression have been conducted. Guided by the question: “What are the effects of ayahuasca in individuals with depression?” this study was a integrative review that aimed to: (1) identify potential therapeutic uses of ayahuasca tea;(2) analyze the safety characteristics and health risks in your use; (3) investigate whether the context of use influences your effects. The search for articles was conducted in the BVS and PubMed databases, produced between 2017-2022, resulting in 8 articles for analysis. The studies showed antidepressant effects resulting from neurochemical interactions and psychological experiences as results of the use of ayahuasca and showed that the safety and therapeutic potential are linked to the context of use and the ingested dosage of the tea.

Downloads

Download data is not yet available.

Author Biographies

Lucas Daniel dos Santos, Pontifícia Universidade Católica do Paraná (PUCPR)

Psicólogo graduado em psicologia pela Pontifícia Universidade Católica do Paraná

Wallisten Passos Garcia, Pontifícia Universidade Católica do Paraná (PUCPR)

Professor no curso de Psicologia da Pontifícia Universidade Católica do Paraná. Mestre em Psicologia e Doutor em Educação.

References

Almeida, R. N., Galvão, A. C. de M., da Silva, F. S., Silva, E. A. dos S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019). Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Frontiers in Psychology, 10, 1234. https://doi.org/10.3389/fpsyg.2019.01234 DOI: https://doi.org/10.3389/fpsyg.2019.01234

American Psychiatric Association (2014). Manual diagnóstico e estatístico de transtornos mentais: DSM-5-TR. 5. ed. Porto Alegre: Artmed.

Aydemir, O., Deveci, A., & Taneli, F. (2005). The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Progress in neuro-psychopharmacology & biological psychiatry, 29(2), 261–265. https://doi.org/10.1016/j.pnpbp.2004.11.009 DOI: https://doi.org/10.1016/j.pnpbp.2004.11.009

Callaway, J. C., Grob, C. S., McKenna, D. J., Nichols, D. E., Shulgin, A., & Tupper, K. W. (2006). A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. Journal of Analytical Toxicology, 30(6), 406–407. https://doi.org/10.1093/jat/30.6.406 DOI: https://doi.org/10.1093/jat/30.6.406

Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020). Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats. Metabolic Brain Disease, 35(5), 739–751. https://doi.org/10.1007/s11011-020-00547-w DOI: https://doi.org/10.1007/s11011-020-00547-w

Costa, M. C. M., Figueiredo, M. C., & Cazenave, S. de O. S. (2005). Ayahuasca: uma abordagem toxicológica do uso ritualístico. Archives of Clinical Psychiatry (São Paulo), 32(6), 310–318. https://doi.org/10.1590/S0101-60832005000600001 DOI: https://doi.org/10.1590/S0101-60832005000600001

Fontes, F. P. X. de. (2017). Os efeitos antidepressivos da ayahuasca, suas bases neurais e relação com a experiência psicodélica. (Tese de Doutorado) -Universidade Federal do Rio Grande do Norte, Natal.

Gable R. S. (2007). Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction (Abingdon, England), 102(1), 24–34. https://doi.org/10.1111/j.1360-0443.2006.01652.x DOI: https://doi.org/10.1111/j.1360-0443.2006.01652.x

Galvão, A. C. d. M., Almeida, R. N., Silva, E. A. do. S., Freire, F. A. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2018). Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Frontiers in Psychiatry, 9(MAY), 1–10. https://doi.org/10.3389/fpsyt.2018.00185. DOI: https://doi.org/10.3389/fpsyt.2018.00185

Galvão-Coelho, N. L., Menezes Galvão, A. C., Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020). Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. Journal of Psychopharmacology, 34(10), 1125–1133. https://doi.org/10.1177/0269881120936486. DOI: https://doi.org/10.1177/0269881120936486

Gios, T. S., Pinheiro, M. C. P., & Calfat, E. L. de B. (2016). Sintomatologia psicótica e ayahuasca: relato de caso. Debates Em Psiquiatria, 6(2), 38–41. https://doi.org/10.25118/2236-918X-6-2-5. DOI: https://doi.org/10.25118/2236-918X-6-2-5

Labate, B. C. & Araújo, W.S (2002) O uso Ritual da Ayahuasca. Campinas, SP: FAPESP/ Mercado das Letras.

Mendes, K. D. S., Silveira, R. C. de C. P., & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, 17(4), 758–764. https://doi.org/10.1590/S0104-07072008000400018. DOI: https://doi.org/10.1590/S0104-07072008000400018

Mian, M. N., Altman, B. R., & Earleywine, M. (2020). Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness. Journal of Psychoactive Drugs, 52(2), 130–137. https://doi.org/10.1080/02791072.2019.1674428. DOI: https://doi.org/10.1080/02791072.2019.1674428

Nash, J. R., & Nutt, D. J. (2005). Pharmacotherapy of anxiety. Handbook of experimental pharmacology, (169), 469–501. https://doi.org/10.1007/3-540-28082-0_17. DOI: https://doi.org/10.1007/3-540-28082-0_17

Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019). Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. Journal of Psychoactive Drugs, 51(2), 135–145. https://doi.org/10.1080/02791072.2019.1567961. DOI: https://doi.org/10.1080/02791072.2019.1567961

Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., Hallak, J. E. C., Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine, 49(4), 655–663. https://doi.org/10.1017/S0033291718001356. DOI: https://doi.org/10.1017/S0033291718001356

Quevedo, J.& Izquierdo, I. (2020) Neurobiologia dos Transtornos Psiquiátricos, Porto Alegre, RS: Artmed.

Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016). Antidepressive and anxiolytic effects of ayahuasca: A systematic literature review of animal and human studies. Revista Brasileira de Psiquiatria, 38(1), 65–72. https://doi.org/10.1590/1516-4446-2015-1701. DOI: https://doi.org/10.1590/1516-4446-2015-1701

Schenberg E. E. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in pharmacology, 9, 733. https://doi.org/10.3389/fphar.2018.00733. DOI: https://doi.org/10.3389/fphar.2018.00733

Schenberg E. E. (2021). Psychedelic drugs as new tools in psychiatric therapeutics. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 43(2), 121–122. https://doi.org/10.1590/1516-4446-2020-0012. DOI: https://doi.org/10.1590/1516-4446-2020-0012

Starcevic V. (2006). Anxiety states: a review of conceptual and treatment issues. Current opinion in psychiatry, 19(1), 79–83. https://doi.org/10.1097/01.yco.0000194146.81024.5a. DOI: https://doi.org/10.1097/01.yco.0000194146.81024.5a

Tupper, K. (2011). Enteógenos e Inteligência Existencial: Plantas Mestres como Instrumentos Cognitivos. Periferia, 3(2), p.499-516. https://doi.org/10.12957/periferia.2011.3946. DOI: https://doi.org/10.12957/periferia.2011.3946

Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021). A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology, 238(7), 1899–1910. https://doi.org/10.1007/s00213-021-05817-8. DOI: https://doi.org/10.1007/s00213-021-05817-8

Wikinski S. (2004). Depresión y ansiedad: de la clínica al tratamiento farmacológico [Depression and anxiety: from clinic to pharmacological treatment]. Vertex (Buenos Aires, Argentina), 15(57), 208–212.